PL2112155T3 - Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania - Google Patents

Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania

Info

Publication number
PL2112155T3
PL2112155T3 PL08155220T PL08155220T PL2112155T3 PL 2112155 T3 PL2112155 T3 PL 2112155T3 PL 08155220 T PL08155220 T PL 08155220T PL 08155220 T PL08155220 T PL 08155220T PL 2112155 T3 PL2112155 T3 PL 2112155T3
Authority
PL
Poland
Prior art keywords
preparation
tetrahydrothieno
cyclopropylcarbonyl
fluorobenzyl
acetoxy
Prior art date
Application number
PL08155220T
Other languages
English (en)
Inventor
Andreas Hotter
Josef Wieser
Arthur Pichler
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of PL2112155T3 publication Critical patent/PL2112155T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL08155220T 2008-04-25 2008-04-25 Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania PL2112155T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08155220A EP2112155B1 (en) 2008-04-25 2008-04-25 Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation

Publications (1)

Publication Number Publication Date
PL2112155T3 true PL2112155T3 (pl) 2011-03-31

Family

ID=39485072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08155220T PL2112155T3 (pl) 2008-04-25 2008-04-25 Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania

Country Status (10)

Country Link
EP (2) EP2112155B1 (pl)
CN (1) CN102076699B (pl)
AT (1) ATE482961T1 (pl)
BR (1) BRPI0910616A2 (pl)
CA (1) CA2722248C (pl)
DE (1) DE602008002820D1 (pl)
EA (1) EA017885B1 (pl)
ES (1) ES2353853T3 (pl)
PL (1) PL2112155T3 (pl)
WO (1) WO2009130289A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350511B1 (en) 2000-12-25 2008-09-10 Daiichi Sankyo Company, Limited Medicinal compositions containing aspirin
JP2011529859A (ja) * 2008-08-02 2011-12-15 ルナン ファーマシューティカル グループ コーポレーション プラスグレル重硫酸塩及びその薬物組成物並びにその応用
EA024980B1 (ru) 2009-02-17 2016-11-30 КРКА, д.д., НОВО МЕСТО Лекарственные формы, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
GB2469883A (en) * 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
EP2360159A1 (de) * 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
EP2377520A1 (de) 2010-03-24 2011-10-19 Ratiopharm GmbH Pharmazeutische Zusammensetzung des Prasugrels
PL2448945T3 (pl) 2010-04-08 2015-06-30 Teva Pharma Krystaliczne postacie soli prasugrelu
CN102675338A (zh) * 2011-03-11 2012-09-19 上海现代制药股份有限公司 微粉化普拉格雷及其药用组合物
CN102838617A (zh) * 2011-06-21 2012-12-26 江苏威凯尔医药科技有限公司 (S)-2-(2-烟酰氧基-6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)-2-(2-氯苯基)-乙酸甲酯的多晶型物和药物组合物
CN102838618A (zh) * 2011-06-22 2012-12-26 广东东阳光药业有限公司 一种制备普拉格雷的方法及普拉格雷盐酸盐新晶型
JP2014524929A (ja) * 2011-07-28 2014-09-25 ラボラトリオス レスヴィ，エス．エル． プラスグレルの調製方法
CN102512415B (zh) * 2011-12-16 2013-07-31 山东齐都药业有限公司 一种硫酸氢氯吡格雷药物组合物及制备方法
US8603537B2 (en) * 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
CN102977116B (zh) * 2012-12-24 2014-12-03 天津大学 一种无定形普拉格雷硫酸氢盐及其制备方法
EP2979693A1 (en) * 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
CN107814810A (zh) * 2016-09-14 2018-03-20 天津科技大学 一种普拉格雷硫酸氢盐新晶型及其制备方法
CN107915743A (zh) * 2016-10-10 2018-04-17 天津科技大学 一种普拉格雷硫酸氢盐晶型iv及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
CA2703697C (en) 2000-07-06 2012-09-04 Daiichi Sankyo Company, Limited Acid addition salts of hydropyridine derivatives
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
GB0325603D0 (en) 2003-11-03 2003-12-10 Sandoz Ag Organic compounds
EP1888037A2 (en) 2005-05-10 2008-02-20 Elan Pharma International Limited Nanoparticulate clopidogrel formulations
TWI318571B (en) 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
JP2009504737A (ja) 2005-08-19 2009-02-05 イーライ リリー アンド カンパニー 脈管疾患の治療又は予防のためのｐａｒ−１／ｐａｒ−４阻害剤の使用
WO2007027454A1 (en) 2005-08-30 2007-03-08 Bristol-Myers Squibb Company Heterocyclic dihydropyrimidine compounds
JP2009532462A (ja) 2006-04-05 2009-09-10 カディラ・ヘルスケア・リミテッド 調節放出クロピドグレル製剤
TWI392681B (zh) 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法

Also Published As

Publication number Publication date
WO2009130289A1 (en) 2009-10-29
CN102076699B (zh) 2013-11-13
ATE482961T1 (de) 2010-10-15
EP2112155B1 (en) 2010-09-29
DE602008002820D1 (de) 2010-11-11
BRPI0910616A2 (pt) 2019-10-29
ES2353853T3 (es) 2011-03-07
EA201001548A1 (ru) 2011-06-30
CA2722248C (en) 2016-06-28
EP2285812A1 (en) 2011-02-23
CN102076699A (zh) 2011-05-25
EA017885B1 (ru) 2013-03-29
EP2112155A1 (en) 2009-10-28
CA2722248A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
PL2112155T3 (pl) Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania
IL212716A0 (en) Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer
MX343274B (es) Inhibidores de la replicacion del vih.
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
BG108868A (en) Polymorphs of clopidogrel hydrochloride and their use as antithrombic compounds
SG10201402977WA (en) Pyrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
IL215074A0 (en) Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
CY1115917T1 (el) Νεες κρυσταλλικες πολυμορφες κλοπιδογρελης
PH12012501693A1 (en) 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
IL189667A0 (en) 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
WO2011042860A3 (en) New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria
EP2549874A4 (en) SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
TNSN06311A1 (en) Clopidogrel salt and polymorphic forms thereof
UA83919C2 (en) Polymorphic forms of methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate hydrobromide, clopidrogel hydrobromide
EA201290535A1 (ru) Способ получения фармацевтических соединений и промежуточных соединений
WO2008108742A3 (en) Polymorphic forms of clopidogrel hydrobromide
HU0600194D0 (en) Process for producing (s)-(+)-methyl-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetate hidrogen sulfate polimorph i
HUP0600920A3 (en) Substituted thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them
WO2005003138A3 (en) Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
WO2007032023A3 (en) A process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetic acid methyl ester or salts thereof having higher chiral purity and products thereof
HUP0600919A3 (en) 7h-thieno[2,3-b]pyridin-6-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HU0700809D0 (en) Racemisation process for producing methyl (r,s)-(+)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4h)-acetate hydrogene sulfate intermediate
SG156645A1 (en) Method for cleaning 3-hydroxyamidinophenylalanine derivatives by the precipitation and recrystallization of salt and an aromatic sulfonic acid